Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Mallinckrodt
Daiichi Sankyo
Covington
Citi
Healthtrust
US Department of Justice
Dow
Merck

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: RE39198

« Back to Dashboard

Which drugs does patent RE39198 protect, and when does it expire?


Patent RE39198 protects FANAPT and is included in one NDA. There has been one Paragraph IV challenge on Fanapt.

This patent has one hundred and twenty-six patent family members in thirty countries.

Summary for Patent: RE39198

Title:Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Abstract:Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s): Strupczewski; Joseph T. (Flemington, NJ), Helsley; Grover C. (Rosemont, NJ), Chiang; Yulin (Convent Station, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Glamkowski; Edward J. (Warren, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/712,129
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-001May 6, 2009ABRXYesYes► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► SubscribeYY INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE39198

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,580,887 1- (arylthioalkyl , arylaminoalkyl or arylmethylenealkyl) -4- (heteroaryl) piperidines and related compounds useful as anti-psychotics and analgesics► Subscribe
5,612,342 United States Patent: 5612342   ( 1► Subscribe
6,140,345 1-(aryloxyalkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics► Subscribe
5,599,821 4-heteroaryl-1-piperidinealkylamines and derivatives thereof and their therapeutic utility► Subscribe
5,663,449 Intermediate compounds in the synthesis of heteroarylpiperidines, pyrrolidines and piperazines► Subscribe
RE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics► Subscribe
5,580,875 1-[(2-pyrimidinyloxy)alkyl]-3-(heteroaryl)pyrrolidines and related compounds and therapeutic utility► Subscribe
5,589,495 2-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-1,3- indandiones and related compounds and their therapeutic utility► Subscribe
5,364,866 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics► Subscribe
5,776,963 3-(heteroaryl)-1-[(2,3-dihydro-1h-isoindol-2-yl)alkyl]pyrrolidines and 3-(heteroaryl)-1-[(2,3-dihydro-1h-indol-1-yl)alkyl]pyrrolidines and related compounds and their therapeutic untility► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE39198

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria126512► Subscribe
Austria248825► Subscribe
Austria356123► Subscribe
Austria485293► Subscribe
Australia1775497► Subscribe
Australia3057092► Subscribe
Australia5577090► Subscribe
Australia640653► Subscribe
Australia674499► Subscribe
Australia709451► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
Chubb
QuintilesIMS
Fuji
Medtronic
Baxter
US Department of Justice
Novartis
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot